临床开发计划如何帮助药物项目? 博客 临床开发计划如何帮助药物项目? How important is a clinical development plan? Your biotechnology start-up’s candidate asset has an intriguing…Certara2024 年 7 月 26 日
A guide to developing population files for physiologically-based pharmacokinetic modeling in the Simcyp Simulator Publication 在 Simcyp Simulator 中开发基于生理的药代动力学模型人群文件指南 This collaborative effort by Certara and the Centre for Applied Pharmacokinetic Research (CAPKR) at The…Danielle Pillsbury2024 年 7 月 24 日
A literature review of drug transport mechanisms during lactation Publication A literature review of drug transport mechanisms during lactation The literature review titled "A literature review of drug transport mechanisms during lactation," authored by…Danielle Pillsbury2024 年 7 月 7 日
临床元数据存储库应该做些什么? 博客 临床元数据存储库应该做什么? 2024 年 4 月 4 日 As the clinical research industry moves towards more efficient and automated processes, clinical…Certara2024 年 4 月 4 日
Everything You Need to Know About CRFs in Clinical Trials Blog 关于临床试验中的 CRFs,您需要知道的一切 Read about the basics of CRFs and eCRF design, why annotated CRFs should be standardized…Certara2024 年 3 月 26 日
How Clinical Trial Software Helps Make Studies More Efficient Blog 临床试验软件如何帮助提高研究效率 2024 年 3 月 13 日 Clinical trials play a crucial role in advancing medical research and improving…Certara2024 年 3 月 13 日
Guide to development of compound files for PBPK modeling in the Simcyp population-based simulator Publication Simcyp 群体模拟器中 PBPK 建模复合文件开发指南 The Simcyp Simulator is a software platform for population physiologically-based pharmacokinetic (PBPK) modeling and simulation.…Jim Gallagher2024 年 2 月 23 日
Interlaboratory Variability in the Madin–Darby Canine Kidney Cell Proteome Publication Interlaboratory Variability in the Madin–Darby Canine Kidney Cell Proteome Madin–Darby canine kidney (MDCK) cells are widely used to study epithelial cell functionality. Their low…Danielle Pillsbury2023 年 6 月 28 日
The Essential Components of Your Drug’s Biomarker Strategy White Paper The Essential Components of Your Drug’s Biomarker Strategy Jim Gallagher2022 年 1 月 14 日
More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-mediated Clearances Publication More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-mediated Clearances Rosuvastatin is a substrate of choice in clinical studies of organic anion-transporting polypeptide (OATP)1B1- and…webdev2016 年 7 月 1 日